This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -68.97% and -1.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Avnet, CACI International, Schrodinger and GrowGeneration
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Avnet, CACI International, Schrodinger and GrowGeneration
Is a Surprise Coming for Schrodinger (SDGR) This Earnings Season?
by Zacks Equity Research
Schrodinger (SDGR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Mid-Cap Stocks to Buy Ahead of Earnings Results This week
by Nalak Das
The four mid-cap stocks discussed here are slated to release earnings results this week. These are CACI, SDGR, AVT and GRWG.
National Vision (EYE) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
National Vision (EYE) is expected to report sequentially better results for the second quarter on gradual reopening of stores and return toward more normal operations.
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Schrodinger, Inc. (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Harrow Health (HROW) in Q2 Earnings?
by Zacks Equity Research
Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.
Schrodinger (SDGR) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Schrodinger (SDGR) has been struggling lately, but the selling pressure may be coming to an end soon.
Schrodinger, Inc. (SDGR) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 100.00% and 10.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.
Schrodinger, Inc. (SDGR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Nov 24, 2020
by Zacks Equity Research
Companies in the news are: SDGR, IDEX, DPW, RESI
Schrodinger (SDGR) Jumps: Stock Rises 8.5%
by Zacks Equity Research
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Schrodinger (SDGR) Catches Eye: Stock Jumps 9.3%
by Zacks Equity Research
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Medical Products' Earnings Roster for May 13: SDC, STE & More
by Urmimala Biswas
Many medical product companies register strong earnings growth in Q1, riding on huge market adoption of their COVID-19-related support products and growing demand for non-elective procedures.